The analysis of when medication can cost more than bariatric surgery uses published prices to estimate a break-even point. This study used claims for 6,748 patients with a BMI of at least 35 and type 2 diabetes to compare costs from insurance records [1].
Over three years, semaglutide carried the highest out-of-pocket cost at $7,752, against $5,980 for sleeve gastrectomy and $6,591 for gastric bypass. The analysis found no statistically significant difference in total spending, which included payments by the insurer.
On outcomes the surgical arms did better in places. Compared with semaglutide, sleeve gastrectomy was associated with fewer long-term admissions (HR 0.79, 95% CI 0.72–0.86) and fewer major adverse cardiovascular events (HR 0.79, 95% CI 0.66–0.93). Gastric bypass also showed fewer such events (HR 0.71, 95% CI 0.59–0.88) while showing more emergency visits (HR 1.36) and more inpatient admissions (HR 1.25).
Read those outcome numbers with the population in mind. The surgical patients started with higher BMI and more comorbidities. The authors adjust with inverse probability weighting, generalized linear models and instrumental variables, which narrows the problem without removing it, and none of it makes this a randomized comparison.
The review of GLP-1 cost-effectiveness explains how economic models compare spending and health outcomes over time. If surgery is under consideration, the guide to GLP-1 use around bariatric surgery summarizes studies on treatment timing. A separate review of treatment after weight regain covers people who already had surgery. Ask the care team which evidence applies to your situation.